Microbial ecosystems therapeutics: a new paradigm in medicine? - PubMed (original) (raw)
Review
Microbial ecosystems therapeutics: a new paradigm in medicine?
E O Petrof et al. Benef Microbes. 2013.
Abstract
Increasing evidence indicates that the complex microbial ecosystem of the human intestine plays a critical role in protecting the host against disease. This review discusses gut dysbiosis (here defined as a state of imbalance in the gut microbial ecosystem, including overgrowth of some organisms and loss of others) as the foundation for several diseases, and the applicability of refined microbial ecosystem replacement therapies as a future treatment modality. Consistent with the concept of a 'core' microbiome encompassing key functions required for normal intestinal homeostasis, 'Microbial Ecosystem Therapeutics' (MET) would entail replacing a dysfunctional, damaged ecosystem with a fully developed and healthy ecosystem of 'native' intestinal bacteria. Its application in treating Clostridium difficile infection is discussed and possible applications to other diseases such as ulcerative colitis, obesity, necrotising enterocolitis, and regressive-type autism are reviewed. Unlike conventional probiotic therapies that are generally limited to a single strain or at most a few strains of bacteria 'Microbial Ecosystem Therapeutics' would utilise whole bacterial communities derived directly from the human gastrointestinal tract. By taking into account the intrinsic needs of the entire microbial ecosystem, MET would emphasise the rational design of healthy, resilient and robust microbial communities that could be used to maintain or restore human health. More than simply a new probiotic treatment, this emerging paradigm in medicine may lead to novel strategies in treating and managing a wide variety of human diseases.
Similar articles
- Microbial biofilm communities in the gastrointestinal tract.
Macfarlane S. Macfarlane S. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S142-3. doi: 10.1097/MCG.0b013e31816207df. J Clin Gastroenterol. 2008. PMID: 18806707 Review. - Immunology and probiotic impact of the newborn and young children intestinal microflora.
Bezirtzoglou E, Stavropoulou E. Bezirtzoglou E, et al. Anaerobe. 2011 Dec;17(6):369-74. doi: 10.1016/j.anaerobe.2011.03.010. Epub 2011 Apr 16. Anaerobe. 2011. PMID: 21515397 Review. - Proteomics, human gut microbiota and probiotics.
Aires J, Butel MJ. Aires J, et al. Expert Rev Proteomics. 2011 Apr;8(2):279-88. doi: 10.1586/epr.11.5. Expert Rev Proteomics. 2011. PMID: 21501019 Review. - Early development of intestinal microbiota: implications for future health.
Saavedra JM, Dattilo AM. Saavedra JM, et al. Gastroenterol Clin North Am. 2012 Dec;41(4):717-31. doi: 10.1016/j.gtc.2012.08.001. Epub 2012 Oct 1. Gastroenterol Clin North Am. 2012. PMID: 23101683 Review. - Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic.
Hell M, Bernhofer C, Stalzer P, Kern JM, Claassen E. Hell M, et al. Benef Microbes. 2013 Mar 1;4(1):39-51. doi: 10.3920/BM2012.0049. Benef Microbes. 2013. PMID: 23434948 Review.
Cited by
- Invasions of Host-Associated Microbiome Networks.
Murall CL, Abbate JL, Touzel MP, Allen-Vercoe E, Alizon S, Froissart R, McCann K. Murall CL, et al. Adv Ecol Res. 2017;57:201-281. doi: 10.1016/bs.aecr.2016.11.002. Adv Ecol Res. 2017. PMID: 39404686 Free PMC article. - Colorectal Cancer Immunotherapy: State of the Art and Future Directions.
Cornista AM, Giolito MV, Baker K, Hazime H, Dufait I, Datta J, Khumukcham SS, De Ridder M, Roper J, Abreu MT, Breckpot K, Van der Jeught K. Cornista AM, et al. Gastro Hep Adv. 2023;2(8):1103-1119. doi: 10.1016/j.gastha.2023.09.007. Epub 2023 Sep 19. Gastro Hep Adv. 2023. PMID: 38098742 Free PMC article. - Gastrointestinal inflammation by gut microbiota disturbance induces memory impairment in mice.
Jang SE, Lim SM, Jeong JJ, Jang HM, Lee HJ, Han MJ, Kim DH. Jang SE, et al. Mucosal Immunol. 2018 Mar;11(2):369-379. doi: 10.1038/mi.2017.49. Epub 2017 Jun 14. Mucosal Immunol. 2018. PMID: 28612842 - Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis.
Maldonado-Arriaga B, Sandoval-Jiménez S, Rodríguez-Silverio J, Lizeth Alcaráz-Estrada S, Cortés-Espinosa T, Pérez-Cabeza de Vaca R, Licona-Cassani C, Gámez-Valdez JS, Shaw J, Mondragón-Terán P, Hernández-Cortez C, Suárez-Cuenca JA, Castro-Escarpulli G. Maldonado-Arriaga B, et al. Microbiologyopen. 2021 Mar;10(2):e1181. doi: 10.1002/mbo3.1181. Microbiologyopen. 2021. PMID: 33970546 Free PMC article. - Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI).
Claassen E. Claassen E. Front Pharmacol. 2014 Feb 17;5:14. doi: 10.3389/fphar.2014.00014. eCollection 2014. Front Pharmacol. 2014. PMID: 24596557 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous